DistantNews
Support us
Lego켐 Bio Secures Exclusive Rights for Jointly Developed ADC 'LNCB74'
🇰🇷 South Korea /Health & Science

Lego켐 Bio Secures Exclusive Rights for Jointly Developed ADC 'LNCB74'

From Chosun Ilbo · () Korean

Translated from Korean, summarized and contextualized by DistantNews.

At a glance

News Sources not specified New plan
  • Lego켐 Bio has secured exclusive development rights for the antibody-drug conjugate (ADC) 'LNCB74' from its joint development partner, NextCure.
  • The agreement allows Lego켐 Bio to independently make decisions regarding the development, manufacturing, and commercialization of LNCB74.
  • This move grants Lego켐 Bio the sole right to license the technology to third parties.

Lego켐 Bio has transitioned the sole development rights for its B7-H4 targeted antibody-drug conjugate (ADC), LNCB74, from a joint development with U.S. partner NextCure to an independent development model. The company announced on Thursday that it has finalized a conversion and succession agreement with NextCure.

This strategic shift grants Lego켐 Bio complete autonomy over the future trajectory of LNCB74. The company now holds exclusive decision-making power over its development, manufacturing processes, and commercialization strategies. Furthermore, Lego켐 Bio has secured the exclusive rights to license the associated technology to any third parties.

The acquisition of these exclusive rights is a significant step for Lego켐 Bio, potentially enhancing its pipeline and strengthening its position in the competitive ADC market. The B7-H4 target is of interest in oncology, and Lego켐 Bio's control over LNCB74 allows it to pursue its commercialization goals without requiring partner approval for licensing deals.

DistantNews Editorial

Originally published by Chosun Ilbo in Korean. Translated, summarized, and contextualized by our editorial team with added local perspective. Read our editorial standards.

More Stories

From Our Blog